Your browser doesn't support javascript.
loading
Comparison of Levetiracetam and sodium Valproate in the prevention of migraine: a randomized clinical trial study
Article | IMSEAR | ID: sea-199814
ABSTRACT

Background:

Sodium valproate is an anti-seizure drug used for prophylactic use of migraine headaches. Despite the efficacy of this drug due to complications that cause some patients to not tolerate the drug. The purpose of this study was to Comparison of levotiracetam and Sodium valproate in migraine prophylaxis.

Methods:

This is a clinical trials study. 100 migraineurs who referred to the Alavi neurology clinic and indicated the onset of prophylaxis of migraine were studied in two groups of 50, one of which was a group of levetiracetam and another group of sodium valproate Received. Patients received daily 500mg of drug for 3 months and the effect of the drug on the number of attacks, severity of attacks, and MIDAS score was measured. Collected data analyzed by statistical methods in SPSS version 19. P<0.05 was considered as significant.

Results:

In both cases, significant improvement was observed in the number of attacks, severity and MIDAS score. In all of the criteria, levetiracetam and sodium valproate were almost identical, except for reducing the number of headache attacks that had a significantly in levothyramine group less than sodium valporoste group (P = 0.0001).

Conclusions:

This study showed that levothyramineacetamin can be used as a good alternative in those who do not tolerate sodium valproate.

Full text: Available Index: IMSEAR (South-East Asia) Type of study: Controlled clinical trial Year: 2018 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: IMSEAR (South-East Asia) Type of study: Controlled clinical trial Year: 2018 Type: Article